Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 08-24-2010, 06:22 PM   #1
Senior Member
gdpawel's Avatar
Join Date: Aug 2006
Location: Pennsylvania
Posts: 1,080
Medscape: Absolute Benefits of Medical Therapies in Phase III Clinical Trials

In randomized clinical trials of breast and colorectal cancer, new effective adjuvant treatments show decreasing absolute benefit, while new treatments of metastatic disease show unchanging levels of benefit at rapidly escalating costs.

The current research and treatment model makes no difference in outcomes, but adds a lot of profit to researchers, oncologists and pharmaceuticals. How about targeting "individuals" with "individualized" therapy?

From Annals of Oncology

gdpawel is offline   Reply With Quote
Old 08-28-2010, 10:26 AM   #2
Senior Member
gdpawel's Avatar
Join Date: Aug 2006
Location: Pennsylvania
Posts: 1,080
Cancer Clinical Trials are in a State of Crisis

Not good news. And improved treatments will be delayed and patient lives will be lost unless the efficiency and effectiveness of the clinical trials system improves, according to a new report from the Institute of Medicine (IOM), which was commission by the National Cancer Institute to review its Clinical Trials Cooperative Group (CTCG).

At issue are concerns the CTCG program canít conduct timely, large-scale, innovative trials needed to improve patient care. The average time required to design, approve and activate a trial is two years, and only about half of all trials undertaken are completed. Meanwhile, funding since 2002 had dropped 20 percent, while knowledge about predictive biomarkers and molecular changes has grown.

To remedy the problem, the IOM says the CTCG needs to better respond to emerging scientific knowledge; involve broad cooperation of stakeholders; and leverage evolving technologies to provide high-quality research that can change practices.

Four recommended goals:

- Improving speed and efficiency of the design, launch, and conduct of trials;
- Incorporate innovative science and trial design into cancer trials;
- Improving prioritization, selection, support, and completion of clinical trials;
- Provide incentives to patients and physicians to participate.


Last edited by gdpawel; 08-30-2010 at 05:47 AM.. Reason: wrong post
gdpawel is offline   Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump

All times are GMT -7. The time now is 08:36 AM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2019, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter